After Novo Nordisk shut down its cell therapy unit, the AI biotech Cellular Intelligence has contracted neurologist and drug developer Nuno Mendonça to perform due diligence on the Danish company's Parkinson's stem cell therapy program. The move, reported from Montreal on July 10, 2026, signals…
The engagement underscores how Cellular Intelligence, described as an AI biotech, is moving to evaluate an asset that Novo Nordisk has deprioritized. Mendonça, a neurologist with drug development experience, will assess the therapy's preclinical and clinical data, which reportedly led to the biotech's interest in picking up the program.
Novo Nordisk had previously operated a cell therapy unit focused on developing regenerative treatments, including their Parkinson's stem cell candidate. The closure of this unit created an opportunity for other companies to consider acquiring or licensing the technology. Cellular Intelligence's move to bring in an outside expert for due diligence indicates a serious evaluation of the potential of the therapy.
The due diligence process is critical for assessing whether the stem cell therapy can be successfully developed further. Mendonça's role as both a neurologist and an experienced drug developer positions him to evaluate both the scientific merit and the clinical feasibility of the program.
Cellular Intelligence contracted Mendonça specifically to examine the data generated by Novo Nordisk's research team. The company aims to determine if the therapy aligns with its own AI-driven drug development platform. While the exact terms of the due diligence work were not disclosed, the engagement signals that Cellular Intelligence is actively pursuing the asset.
The development stems from the broader trend of major pharmaceutical companies reevaluating their cell therapy portfolios. Novo Nordisk's exit from this specific unit allows smaller, more agile biotechs like Cellular Intelligence to step in and potentially advance the therapy.
Mendonça's expertise in neurology and his track record in drug development make him a suitable choice for this evaluation. The outcome of the due diligence could lead to a licensing deal or acquisition, though no further details have been announced.
As of July 10, 2026, Cellular Intelligence has not publicly stated a timeline for completing the due diligence or what steps would follow a positive evaluation. The company continues to operate from Montreal, leveraging artificial intelligence to identify and develop novel therapies. The Parkinson's stem cell program, if acquired, would represent a significant addition to its pipeline.
Industry observers will be watching for any further announcements regarding the progress of Mendonça's evaluation and whether Cellular Intelligence moves forward with the Novo Nordisk asset. The news highlights the dynamic nature of the cell therapy field, where corporate divestitures can create opportunities for specialized firms.
Related reading: New once-daily pill outperforms oral semaglutide in diabetes trial, Biotech Firms Guard Secrets Amid China Rivalry: Ryan Cross, Democratic Lawmakers Question If Trump Got Unapproved Obesity Drug, GLP-3s Show Promise in Phase 3 Weight Loss and Diabetes Trial.